Wolff-Parkinson-White Syndrome: Evaluation and Management
Initial Evaluation and Risk Stratification
For a patient with WPW syndrome presenting with palpitations, obtain a 12-lead ECG during symptoms to identify the specific arrhythmia, assess hemodynamic stability immediately, and refer symptomatic patients for catheter ablation of the accessory pathway as definitive treatment. 1
Diagnostic Approach
When evaluating a patient with known or suspected WPW presenting with palpitations:
Obtain 12-lead ECG during tachycardia to differentiate between:
- Orthodromic AVRT (narrow QRS, most common)
- Antidromic AVRT (wide QRS with pre-excitation)
- Pre-excited atrial fibrillation (irregularly irregular, wide QRS - life-threatening)
Assess hemodynamic stability: Check blood pressure, mental status, and signs of heart failure or ischemia
Look for high-risk features on baseline ECG:
Acute Management Algorithm
If Hemodynamically UNSTABLE (hypotension, altered mental status, severe symptoms):
Perform immediate synchronized electrical cardioversion - this is Class I recommendation to prevent degeneration to ventricular fibrillation 1, 3. Do not delay for pharmacologic therapy.
If Hemodynamically STABLE:
The management depends critically on QRS width during tachycardia:
Narrow QRS Complex (<120 ms)
- Indicates conduction through AV node (orthodromic AVRT)
- Try vagal maneuvers first
- Adenosine 6 mg rapid IV push (then 12 mg if needed) is safe and effective 2, 4
- If unsuccessful, proceed to synchronized cardioversion
Wide QRS Complex (≥120 ms) - Pre-excited Tachycardia
- Administer IV procainamide or ibutilide to restore sinus rhythm 1, 3
- Alternative agents (Class IIb): IV quinidine, disopyramide, or amiodarone 2, 5
Critical Medication Contraindications
NEVER administer these drugs in WPW with pre-excited AF or wide-complex tachycardia (Class III: Harm):
- Adenosine (in wide/irregular rhythms) 4
- Amiodarone 1
- Digoxin 1
- Diltiazem or verapamil 1, 4
- Beta-blockers (IV administration) 2
These AV nodal blocking agents accelerate conduction through the accessory pathway, potentially causing ventricular fibrillation and sudden death. 1
Definitive Management
Catheter Ablation - The Treatment of Choice
Catheter ablation of the accessory pathway is recommended (Class I) for all symptomatic patients with WPW syndrome, particularly those with: 1, 3
- Any documented arrhythmia episode (including this patient with palpitations)
- History of syncope (suggests rapid rates)
- Short accessory pathway refractory period (<250 ms)
- Pre-excited atrial fibrillation
Key points about ablation:
- Success rates exceed 95% in experienced centers
- Mortality risk 0-1.5% 6
- Prevents life-threatening arrhythmias
- May not prevent AF in older patients - additional therapy may be needed 2, 1
When to Consider Medical Management
If ablation is refused, unavailable, or contraindicated:
- Class IA or IC antiarrhythmics (flecainide, propafenone) prolong accessory pathway refractoriness 6
- Avoid chronic AV nodal blockers as monotherapy
- Medical therapy is inferior to ablation for symptom control and mortality prevention
Risk Stratification for Sudden Death
The incidence of sudden death in WPW is 0-0.6% per year 2. High-risk features requiring urgent ablation:
- Shortest pre-excited R-R interval <250 ms during AF
- Symptomatic tachycardia (especially syncope)
- Multiple accessory pathways
- Inducible rapid pre-excited AF on EP study
Common Pitfalls to Avoid
Never give AV nodal blockers for wide-complex or irregular tachycardia in WPW - this is the most dangerous error and can precipitate ventricular fibrillation 1
Don't assume narrow-complex tachycardia is safe - it can rapidly degenerate to pre-excited AF
Don't delay cardioversion in unstable patients for IV access or medications
Don't discharge symptomatic WPW patients without EP referral - ablation is curative and prevents sudden death 1
Recognize that ablation doesn't always prevent AF - especially in older patients who may need additional rhythm management 2, 1